SCHEMBL5212418

SCHEMBL5212418

CCC(CC)(c1ccc(NC(=O)CCc2oc(-c3n[nH]c4ccccc34)nc2-c2ccc(Cl)cc2)cc1)P(=O)(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
THRB P10828 2/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
NAMPT P43490 3/20 0.38
ROCK1 Q13464 3/20 0.38
POLB P06746 2/20 0.36
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
CETP P11597 2/20 0.36
MAPK8 P45983 2/20 0.36
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208383 0.87 SMO (0.43) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5214830 0.86 MAPT (0.38) MAPTSMN1; SMN2THRBMEN1LMNA
SCHEMBL5213172 0.84 CETP (0.40) MAPTSMN1; SMN2THRBMEN1LMNA
SCHEMBL5212423 0.84 MAPT (0.40) MAPTSMN1; SMN2THRBMEN1LMNA
SCHEMBL5207600 0.83 TP53 (0.44) MAPTMEN1LMNAKMT2ARAB9A
SCHEMBL5208493 0.83 POLB (0.40) MAPTTHRBPOLBTNKSTP53
SCHEMBL5207015 0.82 MAPT (0.41) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL5215005 0.82 PARP3 (0.39) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL5211337 0.82 SMO (0.42) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5210828 0.82 MAPT (0.41) MAPTSMN1; SMN2THRBMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885SMN1; SMN2 584/4885THRB 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.